Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.

TNM 8th Ed (Prognostic)

AJCC 8THBreast Prognostic Stage Groups

Prognostic Classification

The "New" Staging

The AJCC 8th Edition moved from Anatomic Staging (TNM only) to Prognostic Staging, which incorporates Tumor Grade, ER status, PR status, and HER2 status to more accurately reflect survival outcomes.

Outcome Framework

Stage IA

Clinical Strategy

Early-stage prognostic group. Excellent long-term survival expected with standard therapy.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Applied to all patients with invasive breast cancer.
Requires the Anatomical Stage (T, N, M) PLUS Grade, ER status, PR status, and HER2 status.
Used to provide more accurate survival estimates and to qualify patients for clinical trials.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the PREDICT v3.0, Oncotype DX Recurrence, RCB (Residual Cancer Burden) or the Tyrer-Cuzick (IBIS v8) to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

MSI/MMR Interpretation
CML ELTS Score
mRECIST
TNM 8th
CNS-IPI
RCB
BSA
Lugano Classification
FIGO 2021
CLL-IPI
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.